Drug Trial Radar · NCT07804615
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Vima TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve tremor symptoms in adults with Parkinson's disease? * Is VIM0423 well tolerated in individuals with Parkinsons's disease? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Conditions
- PARKINSON DISEASE (Disorder)
Interventions
VIM0423Drug
VIM0423 is a combination drug product containing two active ingredients (VMA-1001 and VMA-1002)
VIM0423 PlaceboDrug
Matching VIM0423 placebo product containing no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)Time frame: From baseline to Week 6
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
Vima Site #039
Scottsdale, Arizona · Not yet recruiting
Vima Site #064
Scottsdale, Arizona · Not yet recruiting
Vima Site #048
Murrieta, California · Recruiting
Vima Site #050
Stamford, Connecticut · Not yet recruiting
Vima Site #065
Altamonte Springs, Florida · Not yet recruiting
Vima Site #054
Aventura, Florida · Not yet recruiting
Vima Site #008
Miami, Florida · Not yet recruiting
Vima Site #046
Naples, Florida · Not yet recruiting
Vima Site #053
Palm Beach, Florida · Not yet recruiting
Vima Site #062
Tampa, Florida · Not yet recruiting
Vima Site #047
Atlanta, Georgia · Not yet recruiting
Vima Site #045
Decatur, Georgia · Recruiting
Vima Site #041
Overland Park, Kansas · Not yet recruiting
Vima Site #043
Baltimore, Maryland · Not yet recruiting
Vima Site #007
Olney, Maryland · Not yet recruiting
Vima Site #002
Farmington Hills, Michigan · Recruiting
Vima Site #014
Albuquerque, New Mexico · Not yet recruiting
Vima Site #055
Amherst, New York · Not yet recruiting
Vima Site #024
New York, New York · Not yet recruiting
Vima Site #052
Patchogue, New York · Not yet recruiting
Vima Site #067
Raleigh, North Carolina · Not yet recruiting
Vima Site #051
Canton, Ohio · Not yet recruiting
Vima Site #016
Memphis, Tennessee · Recruiting
Vima Site #049
Cypress, Texas · Not yet recruiting
Vima Site #063
Dallas, Texas · Not yet recruiting
Vima Site #058
Round Rock, Texas · Not yet recruiting
Vima Site #066
Arlington, Virginia · Not yet recruiting
Vima Site #023
Kirkland, Washington · Not yet recruiting
Vima Site #015
Spokane, Washington · Not yet recruiting
Vima Site #060
Toronto, Ontario, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.